Sorafenib targets Raf serine/threonine kinases (Raf-1, wild-type B-Raf, and oncogenic B-Raf V600E) and VEGFR 1–3 to inhibit tumorigenesis and tumor progression [6]. The gene discussed is MARK2; the disease is neoplasm.